Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? - Wikidata - awgldk - TriplyDB

Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?

Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?

http://www.wikidata.org/entity/Q37427247

about

The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.

P2860

Q34135967-5EDAA80E-C906-4B7A-8A42-991E98F752F1 Q38105019-71F82EDA-82CE-4743-AB40-E2E7A70201A8

P2860

Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?

http://www.wikidata.org/entity/Q37427247

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@en

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@nl

type

label

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@en

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@nl

prefLabel

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@en

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@nl

P1433

Q37427247-BCDA62FD-1877-4F64-9CC8-C676CB6AF629

P1476

Q37427247-2015981E-2BA4-4387-8334-6049CE791107

P2093

Q37427247-83AE36C8-7B9A-48A8-99C7-E7634E2D4F5D

Q37427247-C7CF3D82-8B42-4941-8014-183B298C7026

P2860

Q37427247-02C3CF00-9777-4E13-9A17-FDDB7C8911FE

Q37427247-03B7E71A-7220-4C96-BD87-E85F4F0E0F14

Q37427247-089B097E-1AD2-4177-AB51-16EB65134908

Q37427247-0B82A24D-B87C-44D7-A65E-75709BE49930

Q37427247-14D9CC62-70E9-4523-AA8F-F257F0F2E40D

Q37427247-169CDE2C-1F4B-45D4-89F5-0E54286286D4

Q37427247-19C003DA-98CB-4A96-9029-C47BA1EA8635

Q37427247-1C34F5EA-2722-4BC5-BF77-5BABD2128DAA

Q37427247-2097D611-395F-4409-94DD-B5279C2BF42D

Q37427247-2539AD48-D8E8-488C-AA5B-719B546F2368

P304

Q37427247-F4F9DD34-DFEE-478C-860A-78058FBFA447

P31

Q37427247-2C6B957A-B29A-4229-BFD5-0DE42AD07B63

P356

Q37427247-B7A417BD-CB50-4F38-9908-8EA069DA3412

P407

Q37427247-5CA65E31-9379-481D-89F7-3E3C35E6D3D4

P433

Q37427247-2CC42F18-A332-4054-8DF3-7DE8A98D38A9

P478

Q37427247-51578945-F4B5-4D04-A40D-7F1861122A61

P577

Q37427247-6E11882C-EA93-47B3-88E7-96A363A994DB

P698

Q37427247-9116CC7A-B1EB-45B1-8187-B575E9AD9DFB

P356

PGM.2009.03.1979

P1433

Postgraduate Medicine

P1476

Are renin-angiotensin-aldoster ...... renal outcomes in nephropathy?

@en

P2093

George Bakris

http://www.w3.org/2001/XMLSchema#string

Rigas Kalaitzidis

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Effect of ramipril on the incidence of diabetes.

Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.

Preventing microalbuminuria in type 2 diabetes.

P304

77-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2009.03.1979

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19332965

http://www.w3.org/2001/XMLSchema#string